LONDON – Decode Genetics Inc. has raised the insight genomics brings to the understanding of human disease to a new level through the sequencing of the complete genomes of 2,636 Icelanders, an advance the Amgen Inc. subsidiary claims has deep implications for clinical translation and the rollout of precision medicine. more »
- Morphosys shares fall as Celgene exits MOR202 multiple myeloma alliance
- 'Ohr' maybe not: Phase II miffs Wall Street but outcome useful to empower next stage
- Kura Oncology rewinds interesting drug 'developed in the wrong era'
- PD-1 blockers could branch back into chronic infection
- Drugmakers push for FDA to take the lead in labe...
- Lilly strikes ‘meaningful’ oncology alliance with China’s Innovent; $456M-plus potential
- Brivanib gets a second chance for China’s many liver cancer patients
- Ascletis’ triple therapy HCV drug nails phase II trial in Chinese patients
- Early clinical trial rate slowing in Asia despite obvious advantages
- Immunotherapy combo partnerships, trials gaining...
Arrowhead Research Corp.'s pick-up of the entire RNAi portfolio of Novartis AG earlier this month, including rights to a host of intellectual property (IP) and assets – among them, an existing license agreement with RNAi powerhouse Alnylam Pharmaceuticals Inc. – all but closed the door to big pharma's decade-long experiment in RNAi-based drugs.
Given the precision of chemical synthesis processes, small-molecule drugs can be a surprisingly mixed bag of molecules.
If a molecule has a chiral center, synthesis will give a mixture of two molecules that have the identical chemical composition but are mirror images of each other. Technically speaking, they are enantiomers. In the macrobiological world, a person's left and right hand are enantiomers of each other.READ MORE »
- LDH inhibition shows promise for drug-resistant epilepsy »
- No free lunch between mosquitoes and GMOs »
- Pre-op ANP boosts lung cancer surgery survival »
- Ebola may hamper eradication efforts – for measles »
- Return to pre-antibiotic era? AMR hits developing countries hardest »
- Researchers find a powerful new dengue neutralizing antibody »
- Bench to bedside to bench may bring immunotherapy to solid pediatric tumors »
- Antidepressants might be the best heart drugs around »
- HIV not the only important virus at CROI conference »
- Sharing deeply of ourselves: Still messyMarch 27, 2015 | 11:17 PM | Posted by: Michael Fitzhugh
- Patient engagement as important as the dataFebruary 20, 2015 | 5:50 PM | Posted by: Mari Serebrov
- Listening to the voice that mattersFebruary 04, 2015 | 3:35 PM | Posted by: Mari Serebrov
- States move forward as SEC lags on crowdfunding rulesJanuary 29, 2015 | 6:55 PM | Posted by: Michael Fitzhugh
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trialsDecember 10, 2014 | 8:14 PM | Posted by: Marie Powers
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter